Feb 12 (Reuters) - Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a ...
Heavyweight European venture capital firms like Novo Holdings and Sofinnova Partners have joined together to make the case ...
Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA ...
Novo and Lilly are locked in a tightening fight in the obesity-drug market, with Novo trying to win back its crown after a ...
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around ...
Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Novo Nordisk A/S stock plunged on slowing EPS growth and weak 2026 guidance. Click for this look at the NVO chart and see where the shares may be heading.
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
After industry pressure Hims & Hers stops selling compounded Wegovy pill following HHS and Novo Nordisk actions.
Novo Nordisk sued Hims and Hers Health on Monday over alleged patent infringement after the U.S. telehealth firm launched, ...
Novo Nordisk stock jumps over 8% after rival Hims & Hers withdraws knockoff weight-loss drug amid regulatory scrutiny ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results